Franklin Genomic Advancements ETF
HELX
8 hedge funds and large institutions have $2.57M invested in Franklin Genomic Advancements ETF in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
16% more capital invested
Capital invested by funds: $2.21M → $2.57M (+$361K)
2.74% more ownership
Funds ownership: 20.42% → 23.16% (+2.7%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$457K |
| 2 |
LPL Financial
San Diego,
California
|
+$101K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$39.7K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$217K |
| 2 |
HHGA
Halbert Hargrove Global Advisors
Long Beach,
California
|
-$57K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$47.6K |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$3.6K |
HELX Hedge Fund Activity: Q2 2025 in Review
8 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2025, worth a combined $2.57M — up 16% from $2.21M a quarter earlier.
Fund positioning in HELX was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $457K. The largest seller was Jane Street, exiting entirely with an estimated $217K sold.
- 8 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $2.57M of Franklin Genomic Advancements ETF stock for Q2 2025, up 16% quarter-over-quarter.
- 1 fund opened new Franklin Genomic Advancements ETF positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q2 2025 was Citadel Advisors, an estimated $457K added.
- The largest Franklin Genomic Advancements ETF seller in Q2 2025 was Jane Street, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2025.